|
市場調査レポート
商品コード
1547984
筋弛緩薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測Global Muscle Relaxant Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
||||||
カスタマイズ可能
|
|||||||
| 筋弛緩薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測 |
|
出版日: 2024年07月01日
発行: Value Market Research
ページ情報: 英文 170 Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 図表
- 目次
筋弛緩薬市場の世界需要は、2023年の42億3,000万米ドルから2032年には66億9,000万米ドル近くの市場規模に達すると推定され、調査期間2024～2038年のCAGRは5.22%です。
筋弛緩薬は、痙攣、痛み、脱水や疲労によるけいれんなど、筋肉に引き起こされるいくつかの不快症状の治療に使用される特殊な薬剤クラス別です。これらの薬は中枢神経系には作用しないが、脳と脊髄の間の信号伝達に使われるニューロンに作用します。外科手術の際にも、筋肉を弛緩させるために使用されます。現在FDAによって承認されている筋弛緩薬には、バクロフェン、メタキサロン、オルフェナドリンなどがあります。一般に、筋弛緩薬は非常に強力な薬剤であり、習慣性があり、副作用もあります。ボトックスのような顔のシワ取りに使用される薬剤も、弛緩剤と同じような使用方法であるため、このクラスの薬剤に分類することができます。
市場力学
高齢者人口の増加とライフスタイルの変化が、筋弛緩薬市場の主要促進要因です。世界的に実施される外科手術の数が増加し、患者の筋肉を弛緩させるために麻酔薬とともにこれらの薬剤が使用されることで、この市場の成長がさらに促進される可能性があります。公害の増加や紫外線への暴露は、これらの薬剤を使用して治療することができる特定の皮膚疾患を引き起こす可能性があります。筋弛緩薬市場は、運動不足による筋肉の不調に悩まされる人が多いため、COVID-19による停滞期間中に大きな伸びを示すと考えられます。政府によって課される厳しい規則、薬剤に関連するリスク、高コストは、筋弛緩薬市場の成長を不明瞭にする可能性があります。
調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、筋弛緩薬の世界市場における各セグメントを包括的に評価することもできます。筋弛緩薬産業の成長と動向は、この調査への全体的なアプローチを記載しています。
市場セグメンテーション
筋弛緩薬市場レポートのこのセクションでは、国別と地域別のセグメントに関する詳細なデータを提供することで、戦略担当者がそれぞれの製品またはサービスの対象層を特定し、今後のビジネス機会に役立てることができます。
地域分析
このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける筋弛緩薬市場の現在と将来の需要を強調する地域展望をカバーします。さらに、このレポートでは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。
カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。
目次
第1章 序文
第2章 エグゼクティブサマリー
- 市場のハイライト
- 世界市場スナップショット
第3章 筋弛緩薬-産業分析
- イントロダクション：市場力学
- 市場促進要因
- 市場抑制要因
- 市場機会
- 業界動向
- ポーターのファイブフォース分析
- 市場の魅力分析
第4章 バリューチェーン分析
- バリューチェーン分析
- 原材料分析
- 原材料リスト
- 原材料メーカー一覧
- 主要原材料の価格動向
- 潜在的バイヤー一覧
- マーケティングチャネル
- 直接マーケティング
- 間接マーケティング
- マーケティングチャネル発展動向
第5章 筋弛緩薬の世界市場分析：薬剤タイプ別
- 薬剤タイプ別概要
- 実績データと予測データ
- 薬剤タイプ別分析
- 骨格筋弛緩薬
- 顔面筋弛緩薬
- 神経筋遮断薬
第6章 筋弛緩薬の世界市場分析：投与経路別
- 投与経路別概要
- 実績データと予測データ
- 投与経路別分析
- 経口
- 注射
第7章 筋弛緩薬の世界市場分析：流通チャネル別
- 流通チャネル別概要
- 実績データと予測データ
- 流通チャネル別分析
- 病院薬局
- 小売薬局
- オンライン薬局
第8章 筋弛緩薬の世界市場分析：地域別
- 地域別展望
- イントロダクション
- 北米売上分析
- 概要、実績と予測
- 北米：セグメント別
- 北米：国別
- 米国
- カナダ
- メキシコ
- 欧州売上分析
- 概要、実績と予測
- 欧州：セグメント別
- 欧州：国別
- 英国
- フランス
- ドイツ
- イタリア
- ロシア
- その他の欧州
- アジア太平洋売上分析
- 概要、実績と予測
- アジア太平洋：セグメント別
- アジア太平洋：国別
- 中国
- インド
- 日本
- 韓国
- オーストラリア
- 東南アジア
- その他のアジア太平洋
- ラテンアメリカ売上分析
- 概要、実績と予測
- ラテンアメリカ：セグメント別
- ラテンアメリカ：国別
- ブラジル
- アルゼンチン
- ペルー
- チリ
- その他のラテンアメリカ
- 中東・アフリカ売上分析
- 概要、実績と予測
- 中東・アフリカ：セグメント別
- 中東・アフリカ：国別一覧
- サウジアラビア
- アラブ首長国連邦
- イスラエル
- 南アフリカ
- その他の中東・アフリカ
第9章 筋弛緩薬企業の競合情勢
- 筋弛緩薬市場の競合
- 提携/協力/合意
- 合併・買収
- 新製品の上市
- その他の開発
第10章 企業プロファイル
- 上位企業の市場シェア分析
- 市場集中度
- Amneal Pharmaceuticals LLC
- Ipsen Biopharmaceuticals Inc.
- Merz Pharmaceuticals LLC.
- Par Pharmaceutical
- Endo Pharmaceuticals
- Vertical Pharmaceuticals
- Mallinckrodt
- SteriMax
- Eisai Co. Ltd
- Metacel Pharmaceuticals LLC.
- Teva Pharmaceuticals USA Inc
LIST OF TABLES
- Market Snapshot
- Drivers: Impact Analysis
- Restraints: Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- Analysis By Drug Type (USD MN)
- Skeletal Muscle Relaxant Drugs Market Sales By Geography (USD MN)
- Facial Muscle Relaxant Drugs Market Sales By Geography (USD MN)
- Neuromuscular Blocking Agents Market Sales By Geography (USD MN)
- Analysis By Route of Administration (USD MN)
- Oral Market Sales By Geography (USD MN)
- Injectable Market Sales By Geography (USD MN)
- Analysis By Distribution Channel (USD MN)
- Hospital Pharmacy Market Sales By Geography (USD MN)
- Retail Pharmacy Market Sales By Geography (USD MN)
- Online Pharmacy Market Sales By Geography (USD MN)
- Global Muscle Relaxant Drugs Market Sales By Geography (USD MN)
- North America Market Analysis (USD MN)
- United States Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate By Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- South East Asia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Muscle Relaxant Drugs Report
- Market Research Process
- Market Research Methodology
- Global Muscle Relaxant Drugs Market Size, By Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis By Drug Type
- Market Attractiveness Analysis By Route of Administration
- Market Attractiveness Analysis By Distribution Channel
- Market Attractiveness Analysis By Region
- Value Chain Analysis
- Global Market Analysis By Drug Type (USD MN)
- Skeletal Muscle Relaxant Drugs Market Sales By Geography (USD MN)
- Facial Muscle Relaxant Drugs Market Sales By Geography (USD MN)
- Neuromuscular Blocking Agents Market Sales By Geography (USD MN)
- Global Market Analysis By Route of Administration (USD MN)
- Oral Market Sales By Geography (USD MN)
- Injectable Market Sales By Geography (USD MN)
- Global Market Analysis By Distribution Channel (USD MN)
- Hospital Pharmacy Market Sales By Geography (USD MN)
- Retail Pharmacy Market Sales By Geography (USD MN)
- Online Pharmacy Market Sales By Geography (USD MN)
- Global Market Sales (USD MN)
- North America Market Sales (USD MN)
- Europe Market Sales (USD MN)
- Asia Pacific Market Sales (USD MN)
- Latin America Market Sales (USD MN)
- Middle East & Africa Market Sales (USD MN)
- Recent Development in Industry
- Top Company Market Share Analysis
Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
The global demand for Muscle Relaxant Drugs Market is presumed to reach the market size of nearly USD 6.69 Billion by 2032 from USD 4.23 Billion in 2023 with a CAGR of 5.22% under the study period 2024-2038.
Muscle Relaxant Drugs are a special class of drugs used in the treatment of several discomforts caused to the muscle like spasms, pain, and cramps due to dehydration or fatigue. These drugs do not act on the central nervous system but work on the neurons used for signal transmission between the brain and the spinal cord. They are used during surgical procedures as well to relax the muscles. Few of the muscle relaxant drugs currently in the market approved by the FDA are baclofen, metaxalone, and orphenadrine. Generally, muscle relaxants are very powerful drugs which are addictive and can have side effects. Drugs used for removing wrinkles on the face like Botox can also be fit under this class of drugs since their use is like that of a relaxant.
MARKET DYNAMICS
The growing geriatric population and changing lifestyles are the main drivers of the muscle relaxant drugs market. The rise in the number of surgical procedures carried out globally and the use of these drugs along with anaesthetic to relax a patient's muscle can further propel the growth of this market. Increased rate of pollution and exposure to UV rays can cause certain skin conditions which can be treated using these drugs. The market for muscle relaxant drugs will show a great deal of growth during COVID-19 lockdown since many people can suffer from muscular discomforts due to lack of physical activity. Stringent rules imposed by governments, risks involved, and high costs associated with the drugs can obscure the growth of the muscle relaxant drugs market.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Muscle Relaxant Drugs. The growth and trends of Muscle Relaxant Drugs industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Muscle Relaxant Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Drug Type
- Skeletal Muscle Relaxant Drugs
- Facial Muscle Relaxant Drugs
- Neuromuscular Blocking Agents
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Muscle Relaxant Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Muscle Relaxant Drugs market include Amneal Pharmaceuticals LLC, Ipsen Biopharmaceuticals Inc., Merz Pharmaceuticals LLC., Par Pharmaceutical, Endo Pharmaceuticals, Vertical Pharmaceuticals, Mallinckrodt, SteriMax, Eisai Co. Ltd, Metacel Pharmaceuticals LLC., Teva Pharmaceuticals USA Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3. MUSCLE RELAXANT DRUGS - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend
5. GLOBAL MUSCLE RELAXANT DRUGS MARKET ANALYSIS BY DRUG TYPE
- 5.1. Overview By Drug Type
- 5.2. Historical and Forecast Data
- 5.3. Analysis By Drug Type
- 5.4. Skeletal Muscle Relaxant Drugs Historic and Forecast Sales By Regions
- 5.5. Facial Muscle Relaxant Drugs Historic and Forecast Sales By Regions
- 5.6. Neuromuscular Blocking Agents Historic and Forecast Sales By Regions
6. GLOBAL MUSCLE RELAXANT DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
- 6.1. Overview By Route of Administration
- 6.2. Historical and Forecast Data
- 6.3. Analysis By Route of Administration
- 6.4. Oral Historic and Forecast Sales By Regions
- 6.5. Injectable Historic and Forecast Sales By Regions
7. GLOBAL MUSCLE RELAXANT DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL
- 7.1. Overview By Distribution Channel
- 7.2. Historical and Forecast Data
- 7.3. Analysis By Distribution Channel
- 7.4. Hospital Pharmacy Historic and Forecast Sales By Regions
- 7.5. Retail Pharmacy Historic and Forecast Sales By Regions
- 7.6. Online Pharmacy Historic and Forecast Sales By Regions
8. GLOBAL MUSCLE RELAXANT DRUGS MARKET ANALYSIS BY GEOGRAPHY
- 8.1. Regional Outlook
- 8.2. Introduction
- 8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
- 8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
- 8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
- 8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
- 8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis
9. COMPETITIVE LANDSCAPE OF THE MUSCLE RELAXANT DRUGS COMPANIES
- 9.1. Muscle Relaxant Drugs Market Competition
- 9.2. Partnership/Collaboration/Agreement
- 9.3. Merger And Acquisitions
- 9.4. New Product Launch
- 9.5. Other Developments
10. COMPANY PROFILES OF MUSCLE RELAXANT DRUGS INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Market Concentration Rate
- 10.3. Amneal Pharmaceuticals LLC
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
- 10.4. Ipsen Biopharmaceuticals Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
- 10.5. Merz Pharmaceuticals LLC.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
- 10.6. Par Pharmaceutical
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
- 10.7. Endo Pharmaceuticals
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
- 10.8. Vertical Pharmaceuticals
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
- 10.9. Mallinckrodt
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
- 10.10. SteriMax
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
- 10.11. Eisai Co. Ltd
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
- 10.12. Metacel Pharmaceuticals LLC.
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
- 10.13. Teva Pharmaceuticals USA Inc
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
